Adicet Bio, Inc. — Director's Dealing 2022

Apr 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2022-04-01

Reporting Person: Galimi Francesco (SVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-01	Common Stock	M	7621	$5.97	Acquired	67538	Direct
2022-04-01	Common Stock	S	7621	$21.00	Disposed	59917	Direct
2022-04-04	Common Stock	M	6036	$13.27	Acquired	65953	Direct
2022-04-04	Common Stock	S	6036	$21.00	Disposed	59917	Direct
2022-04-04	Common Stock	M	168	$5.97	Acquired	60085	Direct
2022-04-04	Common Stock	S	168	$21.00	Disposed	59917	Direct
2022-04-04	Common Stock	M	1775	$16.82	Acquired	61692	Direct
2022-04-04	Common Stock	S	1775	$21.00	Disposed	59917	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-01	Employee Stock Option (Right to Buy)	$5.97	M	7621	Disposed	2029-10-15	Common Stock (7621)	Direct
2022-04-04	Employee Stock Option (Right to Buy)	$13.27	M	6036	Disposed	2031-01-12	Common Stock (6036)	Direct
2022-04-04	Employee Stock Option (Right to Buy)	$5.97	M	168	Disposed	2029-10-15	Common Stock (168)	Direct
2022-04-04	Employee Stock Option (Right to Buy)	$16.82	M	1775	Disposed	2031-02-11	Common Stock (1775)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 30, 2021.

F2: A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date.

F3: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F4: A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.

F5: A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates.